Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesZura Bio Limited Class A Ordinary Shares

Zura Bio Limited Class A Ordinary Shares

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.475 USD 0.23 ( 18.95%)
Last update at 2026-11-10T15:20:00Z
VOLUME
6709682
Market Cap
472.44M

Momentum Score

…

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.16
Low
1.50
High
52 Week Price Range
1.88
Low
7.44
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Zura Bio Limited is a NASDAQ-listed biopharmaceutical company whose public filings describe development of therapeutic biologics but provide limited detail on its pipeline. Long-term growth drivers include clinical advancement of its programs, regulatory milestones and potential partnerships or commercialization, and investors may find the company attractive because upside is tied to successful development and licensing outcomes.
The principal risks are clinical and regulatory setbacks and ongoing financing needs that could cause dilution and limit the company's ability to complete development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.24
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-51.01%
Net Debt
-109.41M
ROCE
-67.61%
Diluted EPS TTM
-1.06

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -68.65M -52.40M -60.56M -27.33M -
Minority interest - 0.00M 0.20M 1.59M -
Net income -68.65M -52.40M -60.36M -25.74M -
Selling general administrative 33.16M 30.79M 18.64M 3.47M -
Gross profit -0.05M -0.01M - - -
Reconciled depreciation 0.05M 0.01M 0.00M - -
Ebit -68.65M -52.40M -60.56M -29.63M -46.91M
Ebitda -68.60M -52.39M -60.56M -27.16M -
Depreciation and amortization 0.05M 0.01M 0.17M - -
Operating income -75.25M -55.19M -62.64M -27.16M -
Other operating expenses 75.25M 55.19M 62.64M - -
Tax provision 0.00M 0.00M 0.00M - -
Interest income 6.34M 8.00M 2.19M 0.00M -
Net interest income 6.34M 8.00M 2.19M 0.00M -
Income tax expense 30.70M -7.02M -0.20M - -
Total revenue 0.00M 0.00M 0.00M 0.00M -
Total operating expenses 75.25M 55.19M 62.64M 27.16M -
Cost of revenue 0.05M 0.01M - - -
Total other income expense net 6.60M 2.79M 2.08M -0.17M -
Net income from continuing ops -68.65M -52.40M -60.56M -27.33M -
Net income applicable to common shares - - - -35.33M -46.91M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 113.95M 179.53M 100.84M 141.51M 4.72M
Other current assets 2.90M 2.25M 1.04M 0.02M 0.42M
Total liab 12.41M 19.51M 21.29M 14.82M 12.54M
Total stockholder equity 101.54M 146.81M 59.33M -32.06M -7.82M
Deferred long term liab - - - 3.49M -
Other current liab 11.13M 18.78M 17.55M 10.39M 0.03M
Common stock 0.01M 0.01M 0.00M - -
Capital stock 0.01M 0.01M 0.00M 141.37M 139.38M
Retained earnings -224.55M -155.90M -103.49M -32.06M -7.82M
Other assets - - - 141.47M -
Cash 109.41M 176.50M 99.81M 0.01M 4.72M
Total current liabilities 12.41M 19.51M 20.30M 14.82M 0.04M
Net debt -109.41M -176.50M -99.81M -0.01M -
Short long term debt - - - 0.36M -
Other stockholder equity 326.08M 302.70M 162.82M - -
Total current assets 112.31M 178.74M 100.84M 0.03M 4.72M
Net tangible assets - - - -32.06M -7.82M
Accounts payable 1.28M 0.73M 2.75M 4.43M 0.01M
Non currrent assets other 1.51M 0.70M - 3.49M 139.40M
Non current assets total 1.64M 0.79M 0.00M 3.49M 139.40M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -5.08M -8.00M -12.00M -
Change to liabilities - - - 4.09M 0.23M
Total cashflows from investing activities -0.11M -5.08M -8.00M -13.09M -30.00M
Net borrowings - 0.00M -10.00M 8.29M 8.29M
Total cash from financing activities -2.16M 109.84M 121.29M 16.11M 60.00M
Change to operating activities - - - -0.23M -0.23M
Net income -68.65M -52.40M -60.56M -28.08M -46.91M
Change in cash -67.09M 76.69M 98.24M 1.71M 28.32M
Begin period cash flow 176.50M 99.81M 1.57M 0.00M -
End period cash flow 109.41M 176.50M 99.81M 1.57M -
Total cash from operating activities -64.81M -28.08M -15.05M -1.31M -1.68M
Issuance of capital stock 5.10M 60.76M 116.41M 10.00M -
Depreciation 0.05M 0.01M 0.00M - -
Other cashflows from investing activities - -5.00M -8.00M - -
Other cashflows from financing activities -7.37M 49.09M 14.89M -3.09M -3.09M
Change to netincome - - - 22.90M 45.00M
Capital expenditures 0.11M 0.07M 8.00M 12.00M 0.00M
Change in working capital -3.63M 2.31M 5.12M 3.54M -
Stock based compensation 12.33M 16.80M 9.65M 0.33M -
Other non cash items -4.91M 5.21M 30.74M 22.23M -
Free cash flow -64.93M -28.15M -23.05M -13.20M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ZURA
Zura Bio Limited Class A Ordinary Shares		 0.23
18.95%		 1.48 - - - 2.53 -2.34
NVO
Novo Nordisk A/S		 -0.70
1.70%		 40.67 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.79
0.14%		 550.08 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -6.17
0.67%		 913.79 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Zura Bio Limited Class A Ordinary Shares

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

1489 W. Warm Springs Road, Henderson, NV, United States, 89014

702 825 9872

https://zurabio.com

40

Name Title Year Born
Dr. Someit Sidhu M.D. Founder & Non-Independent Director 1990
Mr. Verender S. Badial Chief Financial Officer 1973
Dr. Michael D. Howell Ph.D. Chief Scientific Officer 1977
Ms. Kimberly Ann Davis Chief Legal Officer & Secretary 1968
Mr. Robert Lisicki President, CEO & COO 1968
Dr. Gary Whale Ph.D. Chief Technology Officer 1974
Ms. Theresa Lowry Chief Human Resources Officer 1974
Mr. David Brady Head of Business Development NA
Dr. Kiran Nistala MBBS, Ph.D. Chief Medical Officer & Head of Development 1973
Dr. Sandeep Chidambar Kulkarni M.D. Co-Founder, CEO & Director 1981

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…